Pharming Group N.V. (PHAR) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	366.4M	376.1M	297.2M	245.3M	205.6M
Cost of Revenue	49.4M	45.5M	35.4M	25.2M	17.6M
Gross Profit	317.1M	330.6M	261.8M	220.1M	188.1M
Operating Expenses
R&D Expense	113.3M	100.4M	83.1M	68.9M	52.5M
SG&A Expense	191.4M	117.4M	99.2M	87.5M	68.9M
General & Admin Expense	67.1M	110.8M	92.1M	80.7M	62.4M
Selling & Marketing Expense	124.3M	6.7M	7.1M	6.8M	6.4M
Other Expenses	—	92.0M	83.1M	86.0M	56.8M
Total Operating Expenses	304.7M	309.8M	265.5M	242.4M	178.2M
Cost and Expenses	354.1M	355.3M	300.9M	267.6M	195.8M
Operating Income (EBIT)	12.4M	20.9M	(3.7M)	(22.3M)	9.9M
Non-Operating
Interest Income	3.7M	2.2M	5.9M	3.5M	85.0K
Interest Expense	14.7M	10.7M	9.0M	6.0M	5.4M
Net Interest Income	(11.0M)	(8.5M)	(3.1M)	(2.4M)	(5.3M)
Other Non-Op Income/Expense	3.5M	(8.0M)	(4.8M)	10.3M	5.1M
Non-Operating Income (excl Interest)	(18.2M)	(2.7M)	(3.9M)	(16.2M)	(10.5M)
EBT (Pre-Tax Income)	15.8M	12.8M	(8.5M)	(12.0M)	15.0M
Income Tax Expense	6.6M	10.3M	3.3M	(1.5M)	1.3M
Bottom Line
Net Income	9.3M	2.9M	(11.8M)	(10.5M)	13.7M
Earnings from Cont. Ops	9.3M	2.5M	(11.8M)	(10.5M)	13.7M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	9.3M	2.9M	(11.8M)	(10.5M)	13.7M
Per Share
Basic EPS	$0.14	$0.04	($0.18)	($0.14)	$0.17
Diluted EPS	$0.13	$0.04	($0.18)	($0.14)	$0.16
Revenue Per Share	$5.22	$5.27	$4.31	$3.73	$2.49
Shares
Basic Shares Outstanding	70.1M	71.3M	68.9M	65.7M	82.5M
Diluted Shares Outstanding	70.1M	71.3M	68.9M	65.7M	84.3M
Profitability Metrics
EBITDA	42.6M	34.8M	16.3M	9.9M	33.5M
D&A	12.1M	11.2M	16.1M	15.9M	13.2M
EBIT	30.6M	23.6M	245.0K	(6.0M)	20.3M

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026